Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW’s JETRO NY Post Ended Because There Was No Request: Govt
October 10, 2017
- Health Minister Questions How to Gauge Success in Outcome-Based CAR-T Pricing in Japan
October 10, 2017
- Revised Ministerial Ordinance on Preventing Distribution of Counterfeit Drugs to Take Effect Jan. 31
October 10, 2017
- 3rd Round of Sakigake Invitations Begin
October 6, 2017
- Social Security Council Members Reiterate Opposition to Reference Pricing for LLPs, or LLP-Gx Uniform Prices
October 6, 2017
- MHLW to Place Priority on “Mutual Understanding” with Industry: Economic Affairs Chief
October 6, 2017
- “Pediatric Treatment”, “Innovation” Excluded from Ethical/Social Factors in Pilot CEA Program: Chuikyo
October 5, 2017
- MHLW Drops 5-Scale CEA Rating, Pitches Slope-Like Price Adjustment Model: Chuikyo
October 5, 2017
- Chuikyo Mulls over Scope of CEA-Based Price Adjustments - Premium Portion or Total NHI Price?
October 5, 2017
- Payers Oppose Price Hikes based on CEA at 1st Joint Meeting: Chuikyo
October 5, 2017
- Chuikyo Members Object to Extension of Prescription Limit for Injectable Ethical Narcotic
October 5, 2017
- MHLW Wants to Introduce Conditional Early Approval System This Month: Minister
October 3, 2017
- MHLW Presents Four Patterns for Review of Clinical Research That Falls Under “Specified Clinical Research” Category
October 2, 2017
- Drug Makers to Be Required to Disclose Donations, Lecture Fees, and Writing Fees Tied to “Specified Clinical Research”
October 2, 2017
- MHLW to Compile Guidelines for Proper Drug Promotion Activities
October 2, 2017
- (Update) Bayer Told to Improve Practice over ADR Reporting Delays, Gets “Verbal Guidance” for Xarelto Survey Fuss
October 2, 2017
- MHLW Unveils Planned Framework for Conditional Early Approval Scheme
September 29, 2017
- Keytruda’s Sakigake Designation Revoked after Opdivo Gastric Cancer Nod
September 29, 2017
- MHLW OKs Japan’s 1st PD-L1 Inhibitor, 8-Week Hep C Med, Ibrance and More
September 28, 2017
- As Complaints of Shortages Grow for Japanese Encephalitis Vaccine, MHLW Plans Centralized Collection/Feedback of Supply-Demand Data for Distributers
September 27, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…